Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.58
-8.1%		$2.84
$1.55
▼
$77.10
$330K2.218.52 million shs146,490 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$245K-0.02242,910 shs88,510 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%-22.55%-9.71%-66.02%-97.37%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%0.00%+100.00%+14.29%-82.22%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.58
-8.1%		$2.84
$1.55
▼
$77.10
$330K2.218.52 million shs146,490 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$245K-0.02242,910 shs88,510 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%-22.55%-9.71%-66.02%-97.37%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%0.00%+100.00%+14.29%-82.22%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TCON, IMCC, SRNE, and AMPE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.01N/AN/A($14.81) per share-0.11
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$60.66N/AN/AN/A-39.62%N/A-58.32%11/16/2026 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/AN/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/A

Latest TCON, IMCC, SRNE, and AMPE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.42N/AN/AN/A$18.23 millionN/A
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$9.92N/A$5.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
5.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
44210,000195,000Not Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949306.34 million536.95 millionNo Data
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data

Recent News About These Companies

TRACON Pharma (OTC:TCON) Stock, Short Interest Report
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/TCON/short-interest
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/30/2921433/10391/en/tracon-pharmaceuticals-announces-it-will-wind-down-operations.html
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/11/2896712/10391/en/tracon-announces-publication-in-clinical-cancer-research-of-phase-2-clinical-data-for-trc102-a-dna-damage-repair-inhibitor-in-recurrent-glioblastoma-patients.html
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?
May 27, 2024  |  bovnews.comB
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call Transcript
May 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tracon-pharmaceuticals-inc-nasdaqtcon-q1-2024-earnings-call-transcript/ar-BB1mqOyK
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/q1-2024-tracon-pharmaceuticals-inc-105310624.html?.tsrc=rss
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-inc-tcon-q1-071015646.html?.tsrc=rss
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
May 14, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/tcon-stock-earnings-tracon-pharma-for-q1-of-2024/?utm_source=Tradesmith&utm_medium=referral
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-reports-first-quarter-200100042.html
Tracon: Q1 Earnings Snapshot
May 14, 2024  |  timesunion.comT
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/14/2881830/10391/en/tracon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update.html
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/07/2877173/10391/en/tracon-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024.html
TRACON Pharmaceuticals Inc
April 26, 2024  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tcon-tracon-pharmaceuticals-inc/vitals
Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update
April 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-reaffirmed-for-tracon-pharmaceuticals-post-reverse-split-and-envafolimab-valuation-update-1033238463
TRACON announces 1-for-20 reverse stock split
April 10, 2024  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/tracon-announces-1for20-reverse-stock-split-93CH-3422554
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
April 10, 2024  |  investorplace.comhttps://investorplace.com/2024/04/wall-street-favorites-3-penny-stocks-with-strong-buy-ratings-for-april-2024/
TRACON Pharmaceuticals, Inc. (TCON)
February 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TCON/history
TRACON Pharma Stock (NASDAQ:TCON), Guidance and Forecast
December 23, 2023  |  benzinga.comhttps://www.benzinga.com/quote/TCON/guidance
Buy Rating for TRACON Pharmaceuticals on Envafolimab’s Promising Trial Outcomes and Strong Market Potential
December 20, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-for-tracon-pharmaceuticals-on-envafolimab-s-promising-trial-outcomes-and-strong-market-potential-1032917786
TCON TRACON Pharmaceuticals, Inc.
November 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/TCON/charting?interval=1Y&source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Aright_rail%7Csection_asset%3Achart_expand

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 10/9/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$1.58 -0.14 (-8.14%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.58 0.00 (0.00%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0008 0.00 (0.00%)
As of 10/9/2026 03:57 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas